Oncocyte Corp Files 10-Q for Q1 2025
Ticker: IMDX · Form: 10-Q · Filed: May 12, 2025 · CIK: 1642380
Sentiment: neutral
Topics: 10-Q, quarterly-report, lease-agreement, financials
Related Tickers: 3M
TL;DR
Oncocyte Corp 10-Q filed. Q1 2025 update. Lease and stock details noted.
AI Summary
Oncocyte Corp filed a 10-Q for the period ending March 31, 2025. The company, formerly known as OncoCyte Corp, is involved in diagnostic substances. Key dates mentioned include August 27, 2021, for a LeaseAgreementMember and April 13, 2022, for SeriesARedeemableConvertiblePreferredStockMember. The filing also references an OfficeSubleaseAgreementMember effective January 1, 2025, through March 31, 2025.
Why It Matters
This filing provides a quarterly update on Oncocyte Corp's financial health and operational status, crucial for investors and stakeholders to assess performance and future outlook.
Risk Assessment
Risk Level: medium — The filing contains specific financial and operational details that could indicate varying levels of risk for investors.
Key Numbers
- 20250331 — Reporting Period End Date (Quarterly financial reporting)
- 20250512 — Filing Date (Date the report was submitted to the SEC)
Key Players & Entities
- Oncocyte Corp (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250512 (date) — Filing Date
- 0000950170-25-069213 (accession_number) — Filing Accession Number
- 2835 (industry_code) — Standard Industrial Classification
- 03 Life Sciences (organization) — Organization Name
- CA (state) — State of Incorporation
- 949-409-7600 (phone_number) — Business Phone
- 20200213 (date) — Former Company Name Change Date
- 20200205 (date) — Former Company Name Change Date
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20250331, indicating the first quarter of 2025.
When was this 10-Q filing submitted to the SEC?
The filing was made on 20250512.
What is Oncocyte Corp's Standard Industrial Classification code?
The SIC code listed is 2835, which corresponds to IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES.
Are there any specific lease agreements mentioned in the filing?
Yes, the filing references a LeaseAgreementMember dated 2021-08-27 and an OfficeSubleaseAgreementMember from 2025-01-01 to 2025-03-31.
Does the filing mention any significant customers or customer concentration risks?
The filing mentions 'CustomerThreeM' in the context of 'us-gaap:CustomerConcentrationRiskMember', suggesting a potential concentration with 3M.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Oncocyte Corp (IMDX).